207_Combined course Presentations
ACCORD 12/0405
CAO/ARO/ AIO-04
NSABP R-04
Endpoint
STAR-01
PETACC-6 FOWARC
PCR
16% both arms
14% vs 19%
12.8% vs 16.5% (p=0.038)
19% vs 21%
11.5% vs 13%
14% vs 27.5%
CRM
4% vs 7%
8% vs 13%
5% vs 6% No data
2% vs 2%
9.2% vs 10% R1/R2
yp Node + (stage III)
29% vs 26%
30% vs 26%
27% vs 26% Not
27% vs 26%
19.9% vs 12.6%
stated
Oxaliplatin Phase III trials: Control arm in red
Made with FlippingBook